Bernard Coulie Sells 12,502 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRXGet Rating) CEO Bernard Coulie sold 12,502 shares of the company’s stock in a transaction on Monday, September 12th. The shares were sold at an average price of $22.54, for a total value of $281,795.08. Following the sale, the chief executive officer now owns 59,273 shares of the company’s stock, valued at $1,336,013.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Bernard Coulie also recently made the following trade(s):

  • On Monday, July 11th, Bernard Coulie sold 15,000 shares of Pliant Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $337,500.00.

Pliant Therapeutics Stock Down 1.4 %

Shares of NASDAQ:PLRX opened at $23.88 on Friday. The business’s 50 day simple moving average is $19.62 and its two-hundred day simple moving average is $11.36. The firm has a market cap of $1.16 billion, a P/E ratio of -7.88 and a beta of 1.47. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.69 and a current ratio of 7.69. Pliant Therapeutics, Inc. has a 52-week low of $3.96 and a 52-week high of $24.81.

Analyst Ratings Changes

A number of equities analysts have recently commented on PLRX shares. Royal Bank of Canada boosted their price target on Pliant Therapeutics from $35.00 to $54.00 in a report on Monday, July 11th. Piper Sandler upped their target price on Pliant Therapeutics from $27.00 to $40.00 in a report on Monday, July 11th. Citigroup began coverage on Pliant Therapeutics in a report on Thursday, September 1st. They issued a “buy” rating and a $36.00 target price for the company. HC Wainwright upped their target price on Pliant Therapeutics from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their price target on Pliant Therapeutics from $28.00 to $36.00 in a research note on Monday, July 11th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $41.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in Pliant Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 1,698,212 shares of the company’s stock worth $11,905,000 after acquiring an additional 10,338 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Pliant Therapeutics by 1.8% in the fourth quarter. Citadel Advisors LLC now owns 1,337,126 shares of the company’s stock worth $18,051,000 after purchasing an additional 23,560 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Pliant Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,232,699 shares of the company’s stock worth $8,642,000 after purchasing an additional 14,289 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Pliant Therapeutics in the fourth quarter worth approximately $15,324,000. Finally, First Light Asset Management LLC raised its stake in shares of Pliant Therapeutics by 87.0% in the second quarter. First Light Asset Management LLC now owns 769,370 shares of the company’s stock worth $6,163,000 after purchasing an additional 358,042 shares during the last quarter. Institutional investors own 67.71% of the company’s stock.

About Pliant Therapeutics

(Get Rating)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.

Read More

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.